Acridones circumvent P-glycoprotein-associated multidrug resistance (MDR) in cancer cells

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 1, 2008, Pages 474-487

  Gopinath, Vadiraj S ^a   Thimmaiah, Padma ^b   Thimmaiah, Kuntebommanahalli N ^b  

^a Safety Pharmacology   (India)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Chemosensitizers; Chloroacridone; MDR1; Multidrug resistance; P Glycoprotein

Indexed keywords

10 (3' N MORPHOLINOPROPYL) 2 CHLOROACRIDONE; 10 (4' N DIETHYLAMINOBUTYL) 2 CHLOROACRIDONE; 10 (4' N MORPHOLINOBUTYL) 2 CHLOROACRIDONE; 10 (4' N PIPERIDINOBUTYL) 2 CHLOROACRIDONE; 10 [3' N [(BETA HYDROXYETHYL)PIPERAZINO]PROPYL] 2 CHLOROACRIDONE; 10 [4' N (METHYLPIPERAZINO)BUTYL] 2 CHLOROACRIDONE; 10 [4' N [(BETA HYDROXYETHYL)PIPERAZINO]BUTYL] 2 CHLOROACRIDONE; 10 [4' N [BIS(HYDROXYETHYL)AMINO]BUTYL] 2 CHLOROACRIDONE; 2 CHLOROACRIDONE DERIVATIVE; ACRIDONE DERIVATIVE; AZIDOPINE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE;

ARTICLE; CANCER CELL; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; HUMAN CELL; IC 50; LIPOPHILICITY; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION;

ACRIDONES; BINDING, COMPETITIVE; CELL LINE; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; HUMANS; HYDROPHOBICITY; INHIBITORY CONCENTRATION 50; P-GLYCOPROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP; VERAPAMIL; VINBLASTINE;

EID: 38049161753     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.09.020     Document Type: Article

References (45)

1. Ling V., and Thompson L.H. J. Cell. Physiol. 83 (1974) 103
2. Gerlach J.H., Endicott J.A., Juranka P.F., Henderson G., Sarangi F., Deuchars K.L., and Ling V. Nature 324 (1986) 485
3. Gros P., Ben Neriah Y., Croop J.M., and Housman D.E. Nature 323 (1986) 728
4. Endicott J.A., and Ling V. Annu. Rev. Biochem. 58 (1989) 137
5. Gottesman M.M., and Pastan I. Annu. Rev. Biochem. 62 (1993) 385
6. Gottesman M.M., Fojo T., and Bates S. Nat. Rev. Cancer 2 (2002) 48
7. Bosch I., and Croop J. Biochim. Biophys. Acta 1288 (1996) F37
8. Borst P., Evers R., Kool M., and Wijnholds J. J. Natl. Cancer Inst. 92 (2000) 1295
9. Kruh G., and Belinsky M. Oncogene 22 (2003) 7537
10. Ambudkar S., Dey S., Hrycyna C., Ramachandra M., Pastan I., and Gottesman M. Annu. Rev. Pharmacol. Toxicol. 31 (1999) 361
11. Cornwell M., Tsuruo T., Gottesman M., and Pastan I. FASEB J. 1 (1987) 51
12. Safa A.R., Glover C.J., Meyers M.B., Biedler J.L., and Felsted R.L. J. Biol. Chem. 261 (1986) 6137
13. Senior A.E., Al-Shawi M.K., and Urbatsch I.L. J. Bioenerg. Biomembr. 27 (1995) 31
14. Sharom F.J. J. Bioenerg. Biomembr. 27 (1995) 15
15. Sandor V., Fojo T., and Bater S. Drug Resist. Updat. 1 (1998) 190
16. Trock B., Leonessa F., and Clarke R. J. Natl. Cancer Inst. 89 (1997) 917
17. Tsuruo T., Iida H., Tsukagoshi S., and Sakurai Y. Cancer Res. 41 (1981) 1967
18. Ford J.M., and Hait W.N. Pharmacol. Rev. 42 (1990) 155
19. Wilson W., Jamis-Dow C., Bryant G., Balis F., Klecker R., Bates S., Chabner B., Steinberg S., Kohler D., and Wittes R. J. Clin. Oncol. 13 (1995) 1985
20. Gaveriaux C., Boesch D., and Jachez B. J. Cell. Pharmacol. 2 (1991) 225
21. Hyafil F., Vergely C., Du Vignaud P., and Grand-Perret T. Cancer Res. 53 (1993) 4595
22. Dantzig A., Shepard R., Cao J., Law K., Ehlhardt W., Baughman T., and Starling J. Cancer Res. 56 (1996) 4171
23. Germann U., Ford P., Schlakhter D., Mason V., and Harding M. Anticancer Drugs 8 (1997) 141
24. Agrawal M., Abraham J., Balis F., Edgerly M., Stein W., Bates S., Fojo T., and Chen C. Clin. Cancer Res. 9 (2003) 650
25. Mistry P., Stewart A., Dangerfield W., Okiji S., Liddle C., Bootle D., Plumb J., Templeton D., and Charlton P. Cancer Res. 61 (2001) 749
26. Martin C., Berridge G., Mistry P., Higgins C., Charlton P., and Callaghan R. Br. J. Pharmacol. 128 (1999) 403
27. Suzuki T., Fukazawa N., and San-nohe K. J. Med. Chem. 40 (1997) 2047
28. Suzuki T., Mabuchi K., and Fukazawa N. Bioorg. Med. Chem. Lett. 9 (1999) 659
29. Horton J.K., Thimmaiah K.N., Altenberg G.A., Germain G.S., Castro A.E., Krishnegowda G., and Houghton P.J. Mol. Pharmacol. 52 (1997) 948
30. Krishnegowda G., Thimmaiah P., Hegde R., Dass C., Houghton P.J., and Thimmaiah K.N. Bioorg. Med. Chem. 10 (2002) 2367
31. Hegde R., Thimmaiah P., Mayur Y.C., Krishnegowda G., Thimmaiah K.N., and Houghton P.J. Eur. J. Med. Chem. 39 (2004) 161
32. Albert A. The Acridines. 2nd ed. (1966), Edward Arnold, London
33. Albert A. Selective Toxicity. 7th ed. (1985), Chapman & Hall, London
34. Radzikowski C., Wysocka-Skrzela B., Jrabowska M., Konapa J., Kereczek-Marawska E., Onoazko K., and Ledochowski Z. Arch. Immunol. Ther. Exp. 19 (1971) 219
35. Pelkowska A., Kowalczyk-Bronisz S.H., Blaszcyzk B., Giel-danowski J., and Patkowski J. Arch. Immunol. Ther. Exp. 22 (1973) 823
36. Chou T.C., Wu T.S., Tzeng C.C., Watanabe K.A., and Su T.L. Phytother. Res. 3 (1989) 237
37. Svoboda G.H., Poore G.A., Simpson P.J., and Boder G.B. J. Pharm. Sci. 55 (1966) 758
38. Butenandt A., Biekert E., and Schafer W. Justus Liebigs Ann. Chem. 632 (1960) 134
39. Butenandt A., Biekert E., and Schafer W. Justus Liebigs Ann. Chem. 632 (1960) 143
40. Ogata M., and Kano H. Tetrahedron 24 (1968) 3725
41. Thimmaiah K.N., Jayashree B.S., Germain G.S., Houghton P.J., and Horton J.K. Oncol. Res. 10 (1998) 29
42. Cornwell M.M., Safa A.R., Felsted R.L., Gottesman M.M., and Pastan I. Proc. Natl. Acad. Sci. U.S.A 83 (1986) 3847
43. Zamora J.M., Pearce H.L., and Beck W.T. Mol. Pharmacol. 33 (1988) 454
44. Thimmaiah K.N., Horton J.K., Xiao-dong Q., Beck W.T., Houghton J.A., and Houghton P.J. Cancer Commun. 2 (1990) 249
45. Laemmli U.K. Nature 227 (1970) 680